Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
The company's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on ...
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, ...
Benzinga (Video) on MSN22h
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking Mixed Analyst ReactionsAmgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback